Edition:
India

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

11.10USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$11.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
130,603
52-wk High
$17.20
52-wk Low
$9.90

Latest Key Developments (Source: Significant Developments)

Cytokinetics enters into second amendment to certain loan and security agreement
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Cytokinetics Inc ::Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015 .Cytokinetics - ‍original loan agreement, as amended by amendment, provides for secured growth capital term loans of up to $50.0 million​.  Full Article

Cytokinetics reports Q3 loss of ‍$0.60/shr​
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Cytokinetics Inc :Cytokinetics, Inc. reports third quarter 2017 financial results.Q3 revenue $6.2 million versus I/B/E/S view $6.5 million.Cytokinetics Inc - qtrly loss per share ‍$0.60​.Cytokinetics Inc- ‍anticipates cash research and development expenses will be in range of $103 million to $107 million for 2017​.  Full Article

Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3
Thursday, 1 Sep 2016 

Cytokinetics Inc : Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3 clinical development . Phase 3 outcomes trial will be conducted by Amgen in collaboration with Cytokinetics .Company and Amgen are also planning a potential exercise performance/cardiac function clinical trial to be conducted by Cytokinetics.  Full Article

Cytokinetics Inc reports q2 2016 financial results
Friday, 29 Jul 2016 

Cytokinetics Inc : Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas . Cytokinetics, Inc. reports second quarter 2016 financial results . Q2 loss per share $0.29 . Q2 revenue $5.8 million versus $6.5 million . Q2 revenue view $10.2 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S . Expect to make a decision regarding advancement of omecamtiv mecarbil to phase 3 in Q3 of 2016 ."We will not update our financial guidance until our Q3 earnings due to recent expansion of our collaboration with Astellas".  Full Article

Cytokinetics, Astellas announce option right for Tirasemtiv
Wednesday, 27 Jul 2016 

Cytokinetics Inc : Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS . Option has potential for more than $100 million in payments associated with exercise of option . To receive $65 million in upfront payments, $30 million in additional sponsored research and development .Companies to extend joint research focused on discovery of skeletal muscle activators through 2017.  Full Article

BRIEF-Cytokinetics files for potential mixed shelf, size undisclosed‍​

* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing ‍​ Source text: http://bit.ly/2hauCBo Further company coverage: